Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin—an epidemiological surveillance study using Japanese large health insurance claims database

Table 4 Clinical variables affecting TDM implementation of arbekacin

Characteristic	Univariate analysis			Multivariate analysis
Characteristic	OR	95% CI	P value	OR	95% CI	P value
Age (years)	1.003	0.985–1.020	0.767	1.006	0.988–1.025	0.504
Sex (male)	1.308	0.509–3.364	0.577	1.222	0.451–3.310	0.693
Duration of arbekacin treatment (days)	1.052	0.970–1.140	0.218	1.073	0.983–1.171	0.121
Number of hospital beds
≤ 199 beds	0.606	0.124–2.953	0.535	0.326	0.051–2.083	0.236
200–499 beds	0.706	0.250–1.995	0.511	0.615	0.188–2.009	0.421
≥ 500 beds	1.657	0.633–4.339	0.304	–	–	–
Clinical departments of prescription of arbekacin
Internal medicine	0.940	0.369–2.396	0.898	1.640	0.462–5.814	0.444
Respiratory medicine	2.632	0.674–10.270	0.164	3.158	0.608–16.403	0.171
Gastroenterology	0.691	0.077–6.228	0.742	0.614	0.046–8.158	0.712
Other departments	0.794	0.262–2.404	0.683	–	–	–
Ward pharmacy service	0.894	0.354–2.260	0.813	0.803	0.302–2.137	0.661

TDM Therapeutic Drug Monitoring, OR odds ratio, 95% CI: 95% confidence interval. The odds ratios of “number of hospital beds ≥500 beds” and “clinical departments of other departments” were not calculated because they had linear dependence with other factors

ISSN: 2055-0294